Literature DB >> 24224745

Surgical outcome of reoperation due to left atrioventricular valve regurgitation after previous correction of complete atrioventricular septal defect.

Edvin Prifti1, Massimo Bonacchi, Arben Baboci, Gabriele Giunti, Klodian Krakulli, Vittorio Vanini.   

Abstract

OBJECTIVES: The aims of this study were to evaluate the early and late outcomes in patients undergoing reoperation due to left atrioventricular valve regurgitation (LAVVR) after initial complete repair (ICR) of complete atrioventricular septal defect (CAVSD). MATERIALS AND
METHOD: Between January 1990 and April 2013, 45 consecutive patients underwent reoperation due to severe LAVVR. The mean age was 7.5 ± 6.2 years. Associated LAVV malformations were found in 22 (49%) patients and associated cardiac malformations in 18 (40%). The mean follow-up was 6.8 ± 2.6 years.
RESULTS: LAVV repair was possible in all patients. There were two hospital deaths (4.5%). Ten patients (22%) required a second reoperation due to severe LAVVR at mean 7.5 ± 8.4 months after the first reoperation. The actuarial overall survival and free-reoperation survival rates at one, three, and five years were 95.4%, 92.8%, and 92.8% and 89%, 80.5%, and 72%, respectively. Multivariate analysis revealed that the associated cardiac malformations, LAVV leaflet prolapse or detachment from the septal patch, associated LAVV malformations, and post-first correction LAVVR grade ≥ 2 were strong predictors for poor overall free-reoperation survival in patients undergoing reoperation due to LAVVR after ICR of various forms of ACVSD.
CONCLUSIONS: Patients with severe LAVVR post-ICR of CAVSD may undergo reoperation with acceptable postoperative mortality and morbidity; however, they are at an increased risk for developing postoperative LAVVR and subsequent reoperation.
© 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2013        PMID: 24224745     DOI: 10.1111/jocs.12231

Source DB:  PubMed          Journal:  J Card Surg        ISSN: 0886-0440            Impact factor:   1.620


  6 in total

1.  Repair of complete atrioventricular septal defect with tetralogy of Fallot.

Authors:  Edvin Prifti
Journal:  Transl Pediatr       Date:  2017-01

2.  Visualization and Quantification of the Unrepaired Complete Atrioventricular Canal Valve Using Open-Source Software.

Authors:  Hannah H Nam; Christian Herz; Andras Lasso; Alana Cianciulli; Maura Flynn; Jing Huang; Zi Wang; Beatriz Paniagua; Jared Vicory; Saleha Kabir; John Simpson; David Harrild; Gerald Marx; Meryl S Cohen; Andrew C Glatz; Matthew A Jolley
Journal:  J Am Soc Echocardiogr       Date:  2022-05-07       Impact factor: 7.722

3.  Modified Single Repair Technique for Complete Atrioventricular Septal Defect: A Propensity Score Matching Analysis.

Authors:  Guanxi Wang; Kai Ma; Kunjing Pang; Zhongdong Hua; Sen Zhang; Lei Qi; Yang Yang; Zicong Feng; Fengqun Mao; Hao Zhang; Shoujun Li
Journal:  Pediatr Cardiol       Date:  2020-01-23       Impact factor: 1.655

4.  Dynamic Annular Modeling of the Unrepaired Complete Atrioventricular Canal Annulus.

Authors:  Hannah H Nam; Patrick V Dinh; Andras Lasso; Christian Herz; Jing Huang; Adriana Posada; Ahmed H Aly; Alison M Pouch; Saleha Kabir; John Simpson; Andrew C Glatz; David M Harrild; Gerald Marx; Gabor Fichtinger; Meryl S Cohen; Matthew A Jolley
Journal:  Ann Thorac Surg       Date:  2020-12-24       Impact factor: 4.330

5.  Factors associated with moderate or severe left atrioventricular valve regurgitation within 30 days of repair of complete atrioventricular septal defect.

Authors:  Marcelo Felipe Kozak; Ana Carolina Leiroz Ferreira Botelho Maisano Kozak; Carlos Henrique De Marchi; Sirio Hassem Sobrinho Junior; Ulisses Alexandre Croti; Airton Camacho Moscardini
Journal:  Rev Bras Cir Cardiovasc       Date:  2015 Jul-Sep

6.  Can Left Atrioventricular Valve Reduction Index (LAVRI) Predict the Surgical Strategy for Repair of Atrioventricular Septal Defect?

Authors:  Anastasia Schleiger; Peter Kramer; Marie Schafstedde; Mustafa Yigitbasi; Friederike Danne; Peter Murin; Mi-Young Cho; Joachim Photiadis; Felix Berger; Stanislav Ovroutski
Journal:  Pediatr Cardiol       Date:  2021-02-12       Impact factor: 1.655

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.